Case 61 Charles River Laboratories

Charles River Lab is a non-clinical Contract Research Organization headquartered in Wilmington, Massachusetts and provides a full suite of products and services that span from target identification and discovery through non-clinical drug development and manufacturing. Charles River Laboratories was founded in the year 1947. The company was incorporated in the year 1994 and completed its IPO in the year 2000. In 2021, Charles River was added to the Standard and Poor’s 500 Stock Index (S&P 500). The stock is traded on the New York Stock Exchange under the symbol CRL. The company is also included in the Dow Jones US Health Care Index, the New York Stock Exchange (NYSE) Arca Biotechnology Index, the NYSE, and Russell indexes. The clients of the company include leading pharmaceutical, biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies, contract research and contract manufacturing organizations, commercial entities, leading hospitals, and government agencies. The company has operations in 100 plus locations in over 20 countries. The average growth rate of revenues and net income were 15% and 22% during the period 2018–2022.